ÂÜÀòÂÒÂ×

Kyle joined MVM Partners, a healthcare-focused private equity fund based in Boston, Massachusetts, and London, UK, in 2017. Prior to MVM, he was a consultant at Bain & Company, working mainly in the healthcare practice to support medical devices and healthcare provider clients. During his undergraduate and graduate education, Kyle was a prolific researcher and writer, publishing a half-dozen peer-reviewed papers on topics ranging from homologous chromosome pairing genetics to orthopedic surgery outcomes. Kyle completed MD studies at Harvard Medical School and MBA studies at Harvard Business School. He also holds an AB in biochemistry from Bowdoin College. Kyle is also a board director of Optinose, Inc. (NASDAQ: OPTN), and GT Medical Technologies, Inc.; he is also an observer on the board of MDxHealth SA (NASDAQ: MDXH).